Study on pregnancy outcomes in women with inflammatory bowel disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the pregnancy and neonatal outcomes in women diagnosed with inflammatory bowel disease (IBD) across multiple centers in the United States. It focuses on the effects of medication use and disease activity during pregnancy, specifically among those taking biologics and immunosuppressants. The study aims to gather data over a period of up to 18 years from birth to better understand the implications of IBD on pregnancy outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Female patients with confirmed IBD diagnoses who are pregnant and taking immunosuppressants and/or biologic therapy

Exclusion Criteria:

* Pregnant female patients younger than 18 years of age
* Confirmed multiple gestation

Where it's running

• Please Contact Jessica Lim For Further Information Regarding Other Sites' Locations
  San Francisco, California, United States Recruiting
• University of California San Francisco
  San Francisco, California, United States Recruiting

Study contacts

• Principal investigator: Uma Mahadevan, MD — University of California, San Francisco
• Study coordinator: Jessica Lim
• Email: jessica.lim@ucsf.edu
• Phone: 415-885-3734

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Fecal Transplants from Dai vs Han Donors for Ulcerative Colitis

  This study tests whether fecal microbiota transplantation from healthy Dai donors improves symptoms in adults with ulcerative colitis more than transplantation from healthy Han donors.

  Recruiting Phase 2 First Affiliated Hospital of Kunming Medical University · Kunming, Yunnan · NCT07814456

• Longitudinal Immunophenotyping of People with Inflammatory Bowel Disease

  This study will follow adults with Crohn's disease or ulcerative colitis (and some healthy relatives) over three years to see how their immune cells change over time and how genetics and diet relate to their disease.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07619547

• Breast milk mirikizumab levels in lactating people using mirikizumab for IBS/IBD

  This study tests how much mirikizumab passes into breast milk for people who are breastfeeding while on mirikizumab for an approved condition.

  Recruiting at 2 sites Phase 4 Eli Lilly and Company · Glenview, Illinois and 19 other locations · NCT07612267

• Real-world use of guselkumab in Crohn’s disease and ulcerative colitis

  This study tests how long guselkumab stays in the bodies of adults with moderate-to-severe Crohn’s disease or ulcerative colitis treated in real-world clinical settings.

  Recruiting Janssen-Cilag A.G., Switzerland · Bern · NCT07532213

• Gut microbiome and metabolites in people with IBD and depression

  This project will test whether gut microbes and metabolites differ in adults with IBD who have depression compared with those without depression and with healthy adults.

  Recruiting Qianfoshan Hospital · Jinan, Shandong · NCT07252427

• Real-world use of guselkumab for adults with moderate-to-severe ulcerative colitis and Crohn's disease in the UK

  This project will see how well guselkumab works for adults with moderate-to-severe ulcerative colitis or Crohn's disease who are starting the treatment in routine UK care.

  Recruiting Janssen-Cilag Ltd. · Harrow · NCT07242248

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.